Skip to Main Content
Contribute Try STAT+ Today

Fibrogen is reeling from the worst case of data manipulation in years, but six weeks after the scandal broke, the drug maker still hasn’t explained why or how it happened, or identify the people responsible.

On a conference call Monday, Fibrogen CEO Enrique Conterno reiterated his “confidence” in the drug maker’s experimental anemia treatment, a pill called roxadustat. But how can anyone — investors, physicians, regulators – trust a company that spent nearly two years touting cardiovascular safety data that turns out to have been falsified?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Adam, great article. The elephant in the room is that Conterno came to Fibrogen to replace a CEO that died unexpectedly. This late CEO had a well known reputation for a high level of control and often discarded conventional wisdom related to drug development for his own preferred approach. I have no idea to what degree that dynamic affects this specific situation, but it definitely adds another delicate aspect to the inquiry.

Comments are closed.